TORONTO, Dec. 23, 2020
/CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company")
(TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated
cannabis leader with core operations in Latin America and Europe, provides a year-end corporate update
on its global operations.
Colombia
- Khiron is the first cannabis company in Colombia to ship THC products
internationally
- Colombian government extends medical health insurance coverage
to THC and CBD medical cannabis products
- Company appoints former Colombia Minister of Finance Juan Carlos Echeverry as an independent member
of its Board of Directors
- On December 9th,
Khiron opens new small-format clinic in Medellin, Colombia's
2nd largest city, as part of the Company's plan to
extend its medical cannabis clinics across Colombia and Latin
America
- Khiron declared a National Strategic Project by the Government
of Colombia, which simplifies and
accelerates administration processes for the Company's strategic
initiatives
- Doctor ZereniaTM telehealth platform attracts
25% of patients from outside of Bogota, expanding national reach
- Patient consultations at Company owned clinics return to pre
COVID-19 levels
Peru
- Company becomes the first private medical cannabis company to
sell both THC and CBD medical cannabis products in Peru. In doing so, it also becomes the first
company to ever export THC from Colombia for commercial purposes
Europe
- Khiron ships medical cannabis products to the UK for Project
Twenty21, which now has more than 8,000 patients who have
registered their interest
- Company's medical cannabis e-learning certification completed
by physicians participating in partnership with the UK's Medical
Cannabis Clinicians Society
"This has been an historic year for Khiron in the advancement of
our business; We are seeing patient volume in our expanding network
of clinics in Colombia, our
telehealth platform is attracting patients across the country, and
with sales in Peru we are the
first company ever to export THC product from Colombia. The global pandemic has made
2020 challenging for the Company, and at times we have had to
suspend certain clinic medical services, however, as we look to
2021 in a position of operational and financial strength, I would
like to recognize the remarkable hard work, dedication and
commitment of our global team," comments Alvaro Torres, Khiron CEO and Director.
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis
company with core operations in Latin
America, and operational activity in Europe and North America. Khiron is the
leading cannabis company in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution and sales, and international
export of both low and high THC medical cannabis products. The
Company has filled medical cannabis prescriptions in Peru and has a presence in Mexico, Uruguay, UK, Spain and also in Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage and patient-oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with KuidaTM
now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is
led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-provides-year-end-corporate-update-301198033.html
SOURCE Khiron Life Sciences Corp.